RespireRx Pharmaceuticals Announces Preliminary Top-Line Analysis of Data from Duke University Phase 2A Clinical Trial of CX1739

Pharmaceutical Investing
Company News

Glen Rock, N.J., September 12, 2016/Globe Newswire – RespireRx Pharmaceuticals Inc. (OTCQB:RSPI) is a leader in the development of medicines for respiratory disorders, including drug-induced respiratory depression (RD) and sleep apneas.

Glen Rock, N.J., September 12, 2016/Globe Newswire – RespireRx Pharmaceuticals Inc. (OTCQB:RSPI) is a leader in the development of medicines for respiratory disorders, including drug-induced respiratory depression (RD) and sleep apneas.
RespireRx is today reporting preliminary top-line data from its Phase 2A clinical trial of CX1739, the Company’s proprietary, orally administered ampakine. CX1739 was determined to be safe and well tolerated, and antagonized the respiratory depressive effects of remifentanil (REMI), a potent opioid, in clinical models of acute opioid overdose and chronic opioid use. These results demonstrate target engagement of AMPA glutamate receptors and confirm the Company’s translational approach to developing medicines for respiratory disorders.
The Duke University School of Medicine initiated this Company-funded Phase 2A clinical trial in March 2016. The dosing and data accumulation phase of the clinical trial was completed in June 2016 and the clinical trial was formally completed on July 11, 2016. Database unblinding occurred on September 7, 2016.
Having demonstrated proof of principle and target engagement, the Company has concluded that further development of CX1739 to determine its potential efficacy in the appropriate clinical indications is warranted, and future studies are being designed and planned.

The Conversation (0)
×